Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 3/20 | 0.57 |
| ▸ | CTSL | P07711 | 3/20 | 0.57 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138320 | 1.00 | CTSV (0.57) | CTSVCTSLSRD5A1SRD5A2NPC1 | |
| SCHEMBL7214919 | 0.91 | SRD5A1 (0.58) | CTSVCTSLSRD5A1SRD5A2NPC1 | |
| SCHEMBL874091 | 0.90 | HTT (0.55) | CTSVCTSLSRD5A1SRD5A2NPC1 | |
| SCHEMBL4469125 | 0.90 | SMN1; SMN2 (0.52) | CTSVCTSLSRD5A1SRD5A2NPC1 | |
| SCHEMBL159448 | 0.90 | HTT (0.55) | CTSVCTSLSRD5A1SRD5A2NPC1 | |
| SCHEMBL340527 | 0.90 | SMN1; SMN2 (0.52) | CTSVCTSLSRD5A1SRD5A2NPC1 | |
| SCHEMBL1892032 | 0.89 | KDM4E (0.66) | CTSVCTSLSRD5A1SRD5A2NPC1 | |
| SCHEMBL1012178 | 0.89 | KDM4E (0.66) | CTSVCTSLSRD5A1SRD5A2NPC1 | |
| SCHEMBL23459152 | 0.88 | KDM4E (0.52) | CTSVCTSLSRD5A1SRD5A2NPC1 | |
| SCHEMBL2089698 | 0.88 | KDM4E (0.52) | CTSVCTSLSRD5A1SRD5A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605353-B2 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | ACADEMIA SINICA (TW) | 2026-04-21 | — | — | US | disclosed |
| EP-4069252-B1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING SS-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (CN) | 2025-12-10 | — | — | EP | disclosed |
| CN-114761025-B | PDIA4 inhibitors and their use for inhibiting beta cell pathologies and for treating diabetes | 施明哲 | 2024-03-12 | — | — | CN | disclosed |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (TW) | 2023-02-16 | — | — | US | disclosed |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (TW) | 2023-02-16 | — | — | US | disclosed |
| CN-115677701-A | Benzo heterocyclic compound and preparation method and application thereof | 昆药集团股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-114761025-A | PDIA4 inhibitor and application thereof in inhibiting beta cell pathology and treating diabetes | 施明哲 | 2022-07-15 | — | — | CN | disclosed |
| US-20220162172-A1 | QUINAZOLINONE COMPOUNDS | CEREPEUT, INC. | 2022-05-26 | — | — | US | disclosed |
| EP-2305633-B1 | Catechol derivative and its use | KISSEI PHARMACEUTICAL (JP) | 2013-03-20 | — | — | EP | disclosed |
| CN-101619042-B | Method for synthesizing aromatic pyrimidine-4(3H)-ketone compounds | UNIV ZHEJIANG TECHNOLOGY | 2011-11-09 | — | — | CN | disclosed |
| EP-2305633-A1 | NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE AND USE OF THE PHARMACEUTICAL COMPOSITION | Kissei Pharmaceutical Co., Ltd. (JP) | 2011-04-06 | — | — | EP | disclosed |
| CN-101619042-A | Method for synthesizing aromatic pyrimidine-4(3H)-ketone compounds | UNIV ZHEJIANG TECHNOLOGY | 2010-01-06 | — | — | CN | disclosed |
| WO-2008020302-A2 | HETEROAROMATIC QUINOLINE-BASED COMPOUNDS AS PHOSPHODIESTERASE (PDE) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162172-A1 | QUINAZOLINONE COMPOUNDS | NDUFAB1, NDUFV1, NDUFV2 | CTSV 2833/4885CTSL 2562/4885SRD5A1 2399/4885 |
| US-12605353-B2 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | PDIA4, PDIA5, PDIA6 | CTSV 2455/4885CTSL 1998/4885SRD5A1 1432/4885 |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | PDIA4, PDIA6, PDIA5 | CTSV 3276/4885CTSL 3730/4885SRD5A1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.